Evidence map›Paper›PMID 39284839›Full record

ArticleScientific reports2024

The cellular prion protein does not affect tau seeding and spreading of sarkosyl-insoluble fractions from Alzheimer's disease.

Julia Sala-Jarque, Vanessa Gil, Pol Andrés-Benito, Inés Martínez-Soria, Pol Picón-Pagès, Félix Hernández, Jesús Ávila, José Luis Lanciego, Mario Nuvolone, Adriano Aguzzi and 3 more

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Julia Sala-Jarque *Molecular and Cellular Neurobiotechnology, Institute for Bioengineering of Catalonia (IBEC), Parc Científic de Barcelona, Baldiri and Reixac 15-21, 08028, Barcelona, Spain.
Vanessa Gil *Molecular and Cellular Neurobiotechnology, Institute for Bioengineering of Catalonia (IBEC), Parc Científic de Barcelona, Baldiri and Reixac 15-21, 08028, Barcelona, Spain.
Pol Andrés-BenitoCiberned (Network Centre of Biomedical Research of Neurodegenerative Diseases), Institute of Health Carlos III, Madrid, Spain.
Inés Martínez-SoriaMolecular and Cellular Neurobiotechnology, Institute for Bioengineering of Catalonia (IBEC), Parc Científic de Barcelona, Baldiri and Reixac 15-21, 08028, Barcelona, Spain.
Pol Picón-PagèsMolecular and Cellular Neurobiotechnology, Institute for Bioengineering of Catalonia (IBEC), Parc Científic de Barcelona, Baldiri and Reixac 15-21, 08028, Barcelona, Spain.
Félix HernándezCiberned (Network Centre of Biomedical Research of Neurodegenerative Diseases), Institute of Health Carlos III, Madrid, Spain.
Jesús ÁvilaCiberned (Network Centre of Biomedical Research of Neurodegenerative Diseases), Institute of Health Carlos III, Madrid, Spain.
José Luis LanciegoCiberned (Network Centre of Biomedical Research of Neurodegenerative Diseases), Institute of Health Carlos III, Madrid, Spain.
Mario NuvoloneInstitute of Neuropathology, University of Zurich, Zurich, Switzerland.
Adriano AguzziAmyloidosis Research and Treatment Center, Foundation Scientific Institute Policlinico San Matteo, Department of Molecular Medicine, University of Pavia, Pavia, Italy.
Rosalina GavínMolecular and Cellular Neurobiotechnology, Institute for Bioengineering of Catalonia (IBEC), Parc Científic de Barcelona, Baldiri and Reixac 15-21, 08028, Barcelona, Spain.
Isidro FerrerCiberned (Network Centre of Biomedical Research of Neurodegenerative Diseases), Institute of Health Carlos III, Madrid, Spain.
José Antonio Del RíoMolecular and Cellular Neurobiotechnology, Institute for Bioengineering of Catalonia (IBEC), Parc Científic de Barcelona, Baldiri and Reixac 15-21, 08028, Barcelona, Spain. jadelrio@ibecbarcelona.eu.

Funding

Agència de Gestió d'Ajuts Universitaris i de Recerca SGR2021-00453Institute of Neuroscience, University of Barcelona MDM-2017-0729'la Caixa' Foundation LCF/PR/HR19/52160007Ministerio de Ciencia e Innovación PRE2022-103197Ministerio de Ciencia e Innovación PRPCDEVTAU PID2021-123714OB-I00
6 · The paper itself

Abstract

The cellular prion protein (PrP

Indexed as

Alzheimer Diseasetau ProteinsAnimalsBrainDisease Models, AnimalHumansMiceMice, TransgenicNeuronsPrion ProteinsPrPC ProteinsSarcosinePrion ProteinsPrnp protein, mousePrPC ProteinsSarcosinesarkosyltau ProteinsAlzheimer’s diseaseMaptPrnpPrPCSeedingSpreadingTau

Identifiers

PMID39284839
PMCPMC11405773

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.